New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report
A 22-year-old male with a history of ulcerative colitis and nephrotic syndrome treated with immunomodulatory agents including vedolizumab and mycophenolic acid developed hyperthyroidism 2 weeks following the first administration of BNT162b2 vaccine (Pfizer- BioNTech COVID-19 vaccine). Graves’ diseas...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-01-01
|
| Series: | European Thyroid Journal |
| Subjects: | |
| Online Access: | https://etj.bioscientifica.com/view/journals/etj/11/4/ETJ-22-0049.xml |
| _version_ | 1828065045373779968 |
|---|---|
| author | Ringo Manta Charlotte Martin Vinciane Muls Kris G Poppe |
| author_facet | Ringo Manta Charlotte Martin Vinciane Muls Kris G Poppe |
| author_sort | Ringo Manta |
| collection | DOAJ |
| description | A 22-year-old male with a history of ulcerative colitis and nephrotic syndrome treated with immunomodulatory agents including vedolizumab and mycophenolic acid developed hyperthyroidism 2 weeks following the first administration of BNT162b2 vaccine (Pfizer- BioNTech COVID-19 vaccine). Graves’ disease (GD) was diagnosed based on the elevated thyrotropin-receptor antibody, thyroid scintigraphy and ultrasound. To this day, four cases of new-onset GD following SARS-CoV-2 vaccine were reported in patients with no previous history of thyroid disease. Two cases of recurrence of GD following SARS-CoV-2 vaccine were also reported. Although the underlying mechanisms of vaccine-induced autoimmunity remain to be clarified, there is a rationale for the association between SARS-CoV-2 vaccination and the development of Th1-mediated diseases, at least in predisposed individuals. The BNT162b2 vaccine could be a trigger for GD in some patients. However, the benefit/risk ratio remains by far in favour of SARS-CoV-2 vaccination considering the potentially higher risk of severe infection in these patients. |
| first_indexed | 2024-04-10T23:09:09Z |
| format | Article |
| id | doaj.art-9784b09f84b34f878cd025e98a7ebb5e |
| institution | Directory Open Access Journal |
| issn | 2235-0802 |
| language | English |
| last_indexed | 2024-04-10T23:09:09Z |
| publishDate | 2023-01-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | European Thyroid Journal |
| spelling | doaj.art-9784b09f84b34f878cd025e98a7ebb5e2023-01-13T07:03:30ZengBioscientificaEuropean Thyroid Journal2235-08022023-01-0111414https://doi.org/10.1530/ETJ-22-0049New-onset Graves’ disease following SARS-CoV-2 vaccination: a case reportRingo Manta0Charlotte Martin1Vinciane Muls2Kris G Poppe3Department of Nuclear Medicine, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, BelgiumDepartment of Infectious Diseases, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, BelgiumDepartment of Gastroenterology and Endoscopy, CHU Saint-Pierre, University Libre de Bruxelles (ULB), Brussels, BelgiumDepartment of Endocrinology, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, BelgiumA 22-year-old male with a history of ulcerative colitis and nephrotic syndrome treated with immunomodulatory agents including vedolizumab and mycophenolic acid developed hyperthyroidism 2 weeks following the first administration of BNT162b2 vaccine (Pfizer- BioNTech COVID-19 vaccine). Graves’ disease (GD) was diagnosed based on the elevated thyrotropin-receptor antibody, thyroid scintigraphy and ultrasound. To this day, four cases of new-onset GD following SARS-CoV-2 vaccine were reported in patients with no previous history of thyroid disease. Two cases of recurrence of GD following SARS-CoV-2 vaccine were also reported. Although the underlying mechanisms of vaccine-induced autoimmunity remain to be clarified, there is a rationale for the association between SARS-CoV-2 vaccination and the development of Th1-mediated diseases, at least in predisposed individuals. The BNT162b2 vaccine could be a trigger for GD in some patients. However, the benefit/risk ratio remains by far in favour of SARS-CoV-2 vaccination considering the potentially higher risk of severe infection in these patients.https://etj.bioscientifica.com/view/journals/etj/11/4/ETJ-22-0049.xmlgraves’ diseasesars-cov-2 vaccineadverse vaccine reactions |
| spellingShingle | Ringo Manta Charlotte Martin Vinciane Muls Kris G Poppe New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report European Thyroid Journal graves’ disease sars-cov-2 vaccine adverse vaccine reactions |
| title | New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report |
| title_full | New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report |
| title_fullStr | New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report |
| title_full_unstemmed | New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report |
| title_short | New-onset Graves’ disease following SARS-CoV-2 vaccination: a case report |
| title_sort | new onset graves disease following sars cov 2 vaccination a case report |
| topic | graves’ disease sars-cov-2 vaccine adverse vaccine reactions |
| url | https://etj.bioscientifica.com/view/journals/etj/11/4/ETJ-22-0049.xml |
| work_keys_str_mv | AT ringomanta newonsetgravesdiseasefollowingsarscov2vaccinationacasereport AT charlottemartin newonsetgravesdiseasefollowingsarscov2vaccinationacasereport AT vincianemuls newonsetgravesdiseasefollowingsarscov2vaccinationacasereport AT krisgpoppe newonsetgravesdiseasefollowingsarscov2vaccinationacasereport |